• Kirsten Riber Bergmann, Karen Broekhuizen, and GroeneveldGeert JanGJCentre for Human Drug Research, Leiden, The Netherlands..
• Centre for Human Drug Research, Leiden, The Netherlands.
• Br J Clin Pharmacol. 2020 Feb 1; 86 (2): 380-385.

AbstractWith this study, we aim to test the hypothesis that the effect of cannabidiol on drop-seizure frequency in patients with Lennox-Gastaut syndrome and Dravet syndrome could be attributed to a drug-drug interaction with clobazam. We performed clinical trial simulations for the effect of 20 mg/kg/day cannabidiol on drop-seizure frequency in patients with Lennox-Gastaut syndrome. We assumed that patients taking 10 or 20 mg clobazam would have a 2- to 7-fold increase in N-desmethylclobazam exposure, whereas patients not taking clobazam would have a median reduction in drop-seizure frequency and a variability in the percent reduction similar to the placebo group. The results show that the effect of cannabidiol on the median reduction in drop-seizure frequency in patients with Lennox-Gastaut syndrome may be explained by a drug-drug interaction with clobazam. This may have important implications for the use of cannabidiol and its Food and Drug Administration registration.© 2019 The British Pharmacological Society.

15 keywords...

hide…